Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003

Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to QRX003 lotion for the treatment of Netherton Syndrome, a rare and severe genetic skin disorder for which there are currently no approved treatments. “We believe that the FDA’s decision to grant Fast Track Designation to QRX003 reflects the urgent unmet need faced by patients and families living with Netherton Syndrome,” said Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals. “Fast Track status enables more frequent communication with the FDA and the potential for accelerated regulatory review pathways, which may help bring the first approved treatment for Netherton Syndrome to patients as quickly as possible.”